Cancer News and Research

Latest Cancer News and Research

CDC receives 2014 Franz Edelman Award for Achievement in Operations Research, Management Sciences

The U.S. Centers for Disease Control and Prevention (CDC), which collaborated with Kid Risk, Inc. to use analytics and operations research to combat the remaining pockets of polio around the world, tonight won the 2014 Franz Edelman Award for Achievement in Operations Research and the Management Sciences at a banquet sponsored by the Institute for Operations Research and the Management Sciences (INFORMS) in Boston.

1 Apr 2014

L.A. Times: More than 9 million uninsured gain coverage

The newspaper's tally draws on state and federal enrollment reports, surveys by consultants and interviews with insurance and government officials. Meanwhile, insurers and others intensify efforts to sign up young customers.

1 Apr 2014

Mobile phones with tobacco screening guidelines offer cessation counseling

Smartphones and tablets may hold the key to getting more clinicians to screen patients for tobacco use and advise smokers on how to quit. Even though tobacco use is the leading cause of preventable disease and death in the U.S., clinicians often don't ask about smoking during patient exams.

1 Apr 2014

New report reveals potential breakthrough in pterygium treatment

A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.

1 Apr 2014

Full-field digital mammography associated with lower recall and biopsy rates, says study

Population-based screening with full-field digital mammography (FFDM) is associated with lower recall and biopsy rates than screen film mammography (SFM), suggesting that FFDM may reduce the number of diagnostic workups and biopsies that do not lead to diagnosis of breast cancer, according to a new study published online in the journal Radiology.

1 Apr 2014

Experimental anticancer compound appears to reverse behaviors associated with schizophrenia

Johns Hopkins researchers say that an experimental anticancer compound appears to have reversed behaviors associated with schizophrenia and restored some lost brain cell function in adolescent mice with a rodent version of the devastating mental illness.

1 Apr 2014

Men with long-term HIV infections at higher risk of developing plaque in their coronary arteries

Men with long-term HIV infections are at higher risk than uninfected men of developing plaque in their coronary arteries, regardless of their other risk factors for coronary artery disease, according to results of a study led by Johns Hopkins researchers. A report on the research appears in the April 1 issue of Annals of Internal Medicine.

1 Apr 2014

Retinoic acid helps turn pre-cancer cells back to normal healthy breast cells

A derivative of vitamin A, known as retinoic acid, found abundantly in sweet potato and carrots, helps turn pre-cancer cells back to normal healthy breast cells, according to research published this month in the International Journal of Oncology. The research could help explain why some clinical studies have been unable to see a benefit of vitamin A on cancer: the vitamin doesn't appear to change the course of full-blown cancer, only pre-cancerous cells, and only works at a very narrow dose.

31 Mar 2014

Solid-dominant lung cancer histology no barrier to segmentectomy

Complete resection with segmentectomy is as effective as lobectomy for patients with solid-dominant clinical stage IA lung adenocarcinoma, Japanese study findings suggest.

31 Mar 2014

Lobar offers no survival advantage over sublobar resections in NSCLC

Patients do not survive significantly longer after lobectomy for non-small-cell lung cancer than after wedge resection or segmentectomy, indicate US study results.

31 Mar 2014

Americans' experience with health law depends on where they live

Some states that embraced the law, like Oregon, have had difficulty enrolling residents because of glitch-ridden online marketplaces, while others like New Hampshire have seen unexpectedly strong enrollments despite prevailing critical views.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

First Edition: March 31, 2014

Today's early morning highlights from the major news organizations offer assessments of the administration's campaign to get people signed up for health care and a look at the issues going forward after today's deadline for most enrollments.

31 Mar 2014

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.

31 Mar 2014

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727.

31 Mar 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

From Clinigen Group 31 Mar 2014

Cancer News and Research

Latest Cancer News and Research

CDC receives 2014 Franz Edelman Award for Achievement in Operations Research, Management Sciences

L.A. Times: More than 9 million uninsured gain coverage

Mobile phones with tobacco screening guidelines offer cessation counseling

New report reveals potential breakthrough in pterygium treatment

Full-field digital mammography associated with lower recall and biopsy rates, says study

Experimental anticancer compound appears to reverse behaviors associated with schizophrenia

Men with long-term HIV infections at higher risk of developing plaque in their coronary arteries

Retinoic acid helps turn pre-cancer cells back to normal healthy breast cells

Solid-dominant lung cancer histology no barrier to segmentectomy

Lobar offers no survival advantage over sublobar resections in NSCLC

Americans' experience with health law depends on where they live

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

First Edition: March 31, 2014

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Newsletters you may be interested in